Ralliant Corporation $RAL Shares Purchased by Canoe Financial LP

Canoe Financial LP boosted its stake in Ralliant Corporation (NYSE:RAL) by 6.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,622 shares of the company’s stock after buying an additional 7,319 shares during the quarter. Canoe Financial LP owned approximately 0.11% of Ralliant worth $4,933,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RAL. Danske Bank A S acquired a new position in shares of Ralliant during the fourth quarter valued at approximately $25,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the third quarter worth approximately $26,000. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant during the fourth quarter worth approximately $26,000. Allworth Financial LP increased its position in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares in the last quarter. Finally, BOKF NA acquired a new position in Ralliant in the 3rd quarter valued at $29,000.

Ralliant Stock Performance

NYSE RAL opened at $72.24 on Monday. The stock’s fifty day moving average is $58.13 and its two-hundred day moving average is $51.25. The firm has a market capitalization of $8.09 billion and a P/E ratio of -6.60. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million during the quarter. The business’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, research analysts anticipate that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.83%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Morgan Stanley raised their price objective on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Barclays upped their target price on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Citigroup raised their price target on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 13th. Finally, Oppenheimer boosted their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ralliant currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.